CRISPR Therapeutics: Favorable Short-Term Prospects
This is a news story, published by Yahoo Finance, that relates primarily to Casgevy news.
Casgevy news
For more Casgevy news, you can click here:
more Casgevy newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
CRISPR stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest CRISPR Therapeutics AG news, CRISPR Therapeutics news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Gene therapy developer CRISPR Therapeutics AGTipRanks
•Health
Health
‘Incoming Regulatory Tailwinds’ to Spur 90% Upside for CRISPR Therapeutics Stock, Says BMO Capital
80% Informative
Gene therapy developer CRISPR Therapeutics AG ( CRSP ) is navigating some regulatory and commercial dynamics.
Its flagship gene therapy product for treating sickle cell disease, Casgevy , faces market hurdles.
Analyst Kostas Biliouris from BMO Capital maintained a Buy rating on the stock and has a $ 97 price target.
CRSP has a Moderate Buy consensus rating based on 12 Buy, six Hold, and one Sell recommendations over the past three months .
CRSP ’s average price target of $ 71.89 implies a 90% upside potential over the next 12 months .
Needham analyst Gil Blum maintained a Buy rating on CRSP earlier this month .
VR Score
80
Informative language
78
Neutral language
27
Article tone
formal
Language
English
Language complexity
52
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
16
Source diversity
2
Affiliate links
no affiliate links
Small business owner?